Emmaus Life Sciences, INC 8-K filings

Emmaus Life Sciences announces a 124% surge in Q2 2026 net revenues, primarily from a new license agreement, alongside reduced operating expenses and a return to profitability.

Emmaus Life Sciences reports an 18% decline in Q1 2026 revenue as generic competition impacts U.S. sales.

Emmaus Life Sciences, Inc. has appointed Henry H. Du to its Board of Directors to fill the vacancy left by Jon Kuwahara.

Emmaus Life Sciences, Inc. announced the resignation of director Jon Kuwahara, effective April 15, 2026.

Emmaus Life Sciences announced a 25% drop in 2025 net revenues to $12.5 million, primarily due to generic competition, despite achieving income from operations.

Emmaus Life Sciences entered an exclusive supply agreement with NeoImmuneTech for Endari in the U.S. and Canada, contingent on regulatory approvals.

Emmaus Life Sciences has granted NeoImmuneTech an exclusive license to market and distribute Endari for sickle cell disease in North America, receiving an upfront payment and royalties.

Emmaus Life Sciences exchanged an outstanding $3 million convertible note for new common stock and a $600,000 convertible promissory note.

Emmaus Life Sciences announced the resignation of director Ian Zwicker, effective December 31, 2025.

Emmaus Life Sciences reported a net loss of $2.1 million in Q3 2025, driven by a 38% revenue decline due to generic competition and increased other expenses.

Emmaus Life Sciences reported a 48% decline in net revenue for the second quarter of 2025, driven by generic competition, leading to an operating loss.

Emmaus Life Sciences, Inc. announced the retirement of its Chief Financial Officer, Yasushi Nagasaki, and the promotion of Hiroko Huynh to Chief Accounting Officer, effective July 1, 2025.

Emmaus Life Sciences reported Q1 2025 net revenues of $2.4 million, comparable to the previous year, and a reduced operating loss of less than $1 million.

Emmaus Life Sciences replaced its independent auditor from Marcum LLP to CBIZ CPAs following CBIZ's acquisition of Marcum's attest business.

Emmaus Life Sciences experienced a nearly 44% decline in net revenues in 2024 due to inventory shortages, despite a reduction in operating expenses.

Emmaus Life Sciences saw a significant improvement in its third-quarter financial results, driven by increased sales and reduced operating expenses, despite a year-to-date revenue decline due to earlier inventory shortages.

Emmaus Life Sciences announces the resignation of director Seah Lim, M.D., Ph.D., effective November 4, 2024, due to personal reasons.

Emmaus Life Sciences has engaged Marcum LLP as their new independent registered public accounting firm, effective for the quarter ended September 30, 2024, and the year ending December 31, 2024.

Emmaus Life Sciences has announced the resignation of a board member and the appointment of a new director, along with changes to the Audit Committee.

Emmaus Life Sciences experienced a 55% decline in net revenues for the first half of 2024 due to supply chain disruptions and faces potential challenges from generic competition.

Emmaus Life Sciences has appointed Willis Lee as its new Chief Executive Officer, effective July 15, 2024, eliminating the interim Co-President structure.

Emmaus Life Sciences saw a significant increase in annual net revenues in 2023, driven by growth in the MENA region and the U.S., but faced challenges due to a late-year inventory shortage.

Emmaus Life Sciences has amended its bylaws to designate the Delaware Court of Chancery and U.S. federal district courts as the exclusive forums for certain legal actions.

Emmaus Life Sciences has issued $9 million in new convertible promissory notes due in 2025, in exchange for existing notes due in 2024, with an increased interest rate and adjusted conversion terms.